ICOS

Jounce Therapeutics to Present at Upcoming Investor Conferences in January

Retrieved on: 
Tuesday, January 4, 2022
Investor, ILT4, Cancer, GLOBE, SELECT, Immune system, NASDAQ, Conference, Gilead Sciences, Therapy, Macrophage, PD-1, ICOS, Patient, Tumor microenvironment, CCR8, LILRB2, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

40th Annual J.P. Morgan Healthcare Conference: A live presentation will take place on Thursday, January 13, 2022 at 12:00 p.m.

Key Points: 
  • 40th Annual J.P. Morgan Healthcare Conference: A live presentation will take place on Thursday, January 13, 2022 at 12:00 p.m.
  • A webcast of each presentation will be available by visiting Events and Presentations in the Investors and Media section of Jounces website at www.jouncetx.com .
  • Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Jounce Therapeutics to Present at Upcoming Investor Conferences in November

Retrieved on: 
Tuesday, November 9, 2021
Cancer, Macrophage, SELECT, ILT4, Therapy, Investor, NASDAQ, Immune system, ICOS, Tumor microenvironment, PD-1, LILRB2, Gilead Sciences, Conference, GLOBE, Patient, CCR8, IND, Fourth, fifth, and sixth derivatives of position, Pharmaceutical industry, Animal

33rd Annual Piper Sandler Healthcare Conference: Fireside chat available for on-demand viewing starting Monday, November 22, 2021 at 10:00 a.m.

Key Points: 
  • 33rd Annual Piper Sandler Healthcare Conference: Fireside chat available for on-demand viewing starting Monday, November 22, 2021 at 10:00 a.m.
  • Webcasts of each fireside chat will be available by visiting Events and Presentations in the Investors and Media section of Jounces website at www.jouncetx.com .
  • Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Jounce Therapeutics Reports Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, November 4, 2021
Constellation, Safety, Immunotherapy, U.S. Securities and Exchange Commission, Gilead Sciences, Private Securities Litigation Reform Act, Marketing, Webcast, Trial of the century, COVID-19, Inflammation, Program, Therapy, Immune system, GLOBE, Toxic epidermal necrolysis, Tumor microenvironment, Macrophage, Ligand, Research, Association, Public expenditure, ICOS, Security (finance), Completeness, RNA, ID, Annual report, Investment, Induction, American Association, CD4, Intellectual property, Immunoglobulin G, LILRB2, Neoplasm, CCR8, PD-L1, PD-1, Patient, NSCLC, Cancer, NASDAQ, Investor, ILT4, Conference, Society for Immunotherapy of Cancer, Pharmaceutical industry, Palladium

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • - Ended the quarter with $249.0 million in cash, cash equivalents and investments -
    CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quarter ended September30, 2021 and provided a corporate update.
  • On September 15th, 2021, Jounce announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors.
  • Third Quarter 2021 Financial Results:
    Cash position: As of September30, 2021, cash, cash equivalents and investments were $249.0 million, compared to $213.2 million as of December31, 2020.
  • License and collaboration revenue: No license or collaboration revenue was recognized in the third quarter of 2021 or 2020.

Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021

Retrieved on: 
Thursday, October 28, 2021
Macrophage, LILRB2, Cancer, SELECT, ICOS, Patient, NASDAQ, Investor, ILT4, Gilead Sciences, CCR8, ID, PD-1, Webcast, Therapy, Immune system, GLOBE, Tumor microenvironment, Pharmaceutical industry

Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m. E.T.

Key Points: 
  • Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m. E.T.
  • To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 6873343.
  • The live webcast can be accessed under Events & Presentations in the Investors and Media section of Jounces website at www.jouncetx.com .
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors

Retrieved on: 
Thursday, October 7, 2021
NASDAQ, Tumor microenvironment, Intellectual property, Neoplasm, Therapy, Ovarian cancer, PD-L1, ILT4, SELECT, COVID-19, Liposarcoma, Macrophage, Marketing, IO, GLOBE, Safety, Cancer, Annual report, Immunoglobulin G, Gilead Sciences, U.S. Securities and Exchange Commission, Induction, Private Securities Litigation Reform Act, Immunotherapy, Ligand, Immune system, Security (finance), ICOS, American Association, Association, LILRB2, POC, Patient, CCR8, Science, Public expenditure, PD-1, Research, Pharmaceutical industry, Platinum

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the initiation of patient enrollment in INNATE tumor-specific expansion cohorts for both JTX-8064 monotherapy and combination therapy of JTX-8064 with its internal PD-1 inhibitor, pimivalimab. JTX-8064, the first tumor-associated macrophage candidate developed from Jounce’s Translational Science Platform, is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage receptor Leukocyte Immunoglobulin Like Receptor B2 (LILRB2/ILT4). By inhibiting LILRB2 binding with its ligands, JTX-8064 reprograms immune-suppressive macrophages to an immune-active state in preclinical studies, potentially enhancing the T cell response and anti-tumor immunity.

Key Points: 
  • We are very pleased to announce that we have started dosing patients in the tumor-specific JTX-8064 monotherapy and pimivalimab combination expansion cohorts of our INNATE study, said Beth Trehu, M.D., chief medical officer at Jounce Therapeutics.
  • We have made enormous progress in INNATE, having advanced the study from initiation of monotherapy dose escalation to the opening of tumor-specific, proof-of-concept, combination expansion cohorts in just nine months.
  • Pimivalimab is currently being assessed in the INNATE Phase 1 trial ( NCT04669899 ) in combination with JTX-8064, a LILRB2 (ILT4) inhibitor.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Sumo Logic Drives Adoption of Continuous Intelligence Across Europe with Customer and Partner Growth

Retrieved on: 
Wednesday, September 15, 2021
Cloud, DACH, EMEA, Illuminate, Software as a service, Automation, Partnership, Security operations center, Technology, Managed services, Information security operations center, Serverless computing, Sumo Logic, Ecosystem, Authority, IOT, Software, Computing, Nasdaq, IGaming Business, Logic, General manager, SOAR, Industry, Catena Media, Solution, MDR, Growth, Collection, Computacenter, Cloud computing, Mars, Name, GLOBE, Best, Organization, API, Acquisition, ICOS, MSSP, Cryptocurrency, Video game, Video game console, Management

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sumo Logic (Nasdaq: SUMO), the pioneer in continuous intelligence, today announced it has expanded its customer base and partner network in Europe. Companies including the likes of Catena Media, Elwood, HelloFresh, Snoop and more have implemented Sumo Logic to support their security, operations and business intelligence initiatives and unify their data analytics strategies. In addition, Sumo Logic will be showcasing how to power modern business with real-time insights across observability and security at its 5th annual Illuminate user conference September 28-29, 2021. The event will feature best practices, customer presentations, technical and thought leader sessions in an interactive virtual experience. Registration to attend the conference online is now open.

Key Points: 
  • Sumo Logic provides a cloud-native continuous intelligence platform for organisations, helping them to understand their software development, security and business operations in real time.
  • This demand has supported our growth in Europe as more customers and partners see those issues in their daily activities, commented Iain Chidgey, Vice President EMEA at Sumo Logic.
  • The Sumo Logic Continuous Intelligence Platform automates the collection, ingestion, and analysis of application, infrastructure, security, and IoT data to derive actionable insights within seconds.
  • Sumo Logic is a trademark or registered trademark of Sumo Logic in the United States and in foreign countries.

Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

Retrieved on: 
Wednesday, September 15, 2021
Constellation, Gilead Sciences, Kearney (consulting firm), U.S. Securities and Exchange Commission, Public expenditure, Therapy, Biotechnology, Science, Macrophage, Board, Private Securities Litigation Reform Act, ILT4, Intellectual property, Immune system, Security (finance), Marketing, Patient, SELECT, Nasdaq, Third Rock Ventures, Â, IND, LILRB2, Annual report, Safety, MorphoSys, Growth, COVID-19, Tumor microenvironment, Partnership, GLOBE, PD-1, Biogen, Cancer, Acquisition, ICOS, Research, Leadership, CCR8, Pharmaceutical industry, Management

Its incredibly exciting to welcome Jigar to our board of directors.

Key Points: 
  • Its incredibly exciting to welcome Jigar to our board of directors.
  • Jounces recent growth, pipeline diversification and partnership strategy are core to its track record as a leader in transforming the immuno-oncology landscape, said Jigar Raythatha.
  • Dr. Pfeffer was a founding member of Jounces board of directors since 2013 and also served as chair of the Jounce board from 2014 to 2016.
  • On behalf of the Jounce Board of Directors, I want to thank Cary for his years of dedication to Jounces science, team and mission, said Perry Karsen, chair of the Board of Jounce Therapeutics.

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

Retrieved on: 
Thursday, September 2, 2021
LILRB2, PD-1, Cancer, ICOS, GLOBE, CCR8, Immune system, Macrophage, Therapy, Tumor microenvironment, Investor, Gilead Sciences, NASDAQ, IND, Fourth, fifth, and sixth derivatives of position, Patient, ILT4, SELECT, Conference, Pharmaceutical industry, Medical device

H.C. Wainwright 23rd Annual Global Investment Conference: Presentation will be available on-demand during the conference, starting on Monday, September 13, 2021 at 7:00 a.m.

Key Points: 
  • H.C. Wainwright 23rd Annual Global Investment Conference: Presentation will be available on-demand during the conference, starting on Monday, September 13, 2021 at 7:00 a.m.
  • Bairds 2021 Global Healthcare Conference: Presentation on Wednesday, September 15, 2021 at 12:15 p.m.
  • Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.